MedTrace Logo

Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma

NCT00555334 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2009-04-01

No results posted yet for this study

Summary

The purpose of the investigators' study is to prospectively evaluate whether nucleoid antiviral therapy will improve the outcome of radiofrequency ablation for hepatocellular carcinoma (HCC).

Conditions

Interventions

PROCEDURE

RFA

radiofrequency ablation

DRUG

lamivudine or entecavir

lamivudine (100mg qd) or entecavir (0.5mg qd) after RFA

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • min-shan chen, doctor · Department of Hepatobilliary Surgery, Cancer Center, Sun Yat-sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2009-12-31
Completion
2010-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00555334 on ClinicalTrials.gov